Antigen News and Research

RSS

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

9 Apr 2010

PSA test distress, study urges caution

A new study wants men to be informed about risks associated with screening for prostate cancer. The research has brought out that the prostate cancer tests can cause significant psychological distress to the men undergoing the screening. 330 men were studied by the University of Bristol as they underwent the tests and after they finished.

9 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010

Antigens of both influenza B virus strains can improve influenza vaccines

Vaccines likely would work better in protecting children from flu if they included both strains of influenza B instead of just one, Saint Louis University research has found.

7 Apr 2010

Emory University researchers develop experimental clinical test for XMRV

The recently discovered retrovirus, xenotropic murine leukemia virus-related virus (XMRV), has been identified in some prostate cancer patients. In light of conflicting data concerning XMRV, standardized diagnostic testing is important to identify patients in which XMRV is present and to determine whether it plays a role in the incidence of prostate cancer.

6 Apr 2010

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a collaboration with VLST Corporation to generate novel multi-antigen specific antibody therapeutics for the treatment of autoimmune and inflammatory disorders. This is the fourth collaboration announced by AnaptysBio during 2010.

5 Apr 2010

New report questions the kinetics of T cell receptors

T cell receptors are among the most important molecules in the immune system because of their role in recognizing the antigens that signal such threats as viruses and cancer. The receptors must also distinguish these threats from the body's own cells to avoid triggering an unwanted immune system response.

5 Apr 2010

Study: Trial vaccine eliminates residual cancer cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

3 Apr 2010

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

3 Apr 2010

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Scientists at the University of Delaware have developed a new method for producing proteins critical to research on cancer, Alzheimer's, and other diseases.

3 Apr 2010

Scientists provide first-ever glimpse of HIV protein structure

Scientists from the California Institute of Technology (Caltech) have provided the first-ever glimpse of the structure of a key protein-gp120-found on the surface of a specific subgroup of the human immunodeficiency virus, HIV-1.

3 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor's aggressiveness and long-term response to treatment.

1 Apr 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

Antigen News and Research

"Nanovaccine" reverses diabetes

Nanotechnology-based vaccine cures mice with type 1 diabetes

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

PSA test distress, study urges caution

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Antigens of both influenza B virus strains can improve influenza vaccines

Emory University researchers develop experimental clinical test for XMRV

AnaptysBio, VLST collaborate to generate novel multi-antigen specific antibody therapeutics

New report questions the kinetics of T cell receptors

Study: Trial vaccine eliminates residual cancer cells in CML patients

Kinetics of T cell receptors: New findings could lead to reevaluation of earlier conclusions

New production method yields hundredsfold more ubiquitylated proteins critical for cancer research

Scientists provide first-ever glimpse of HIV protein structure

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

T-cell cytolytic activity may be effective in clearing HBV infection

U.Va. develops Prostate Exam Simulator

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Presence of PARP protein in tumours can help predict their response to chemotherapy

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics